Global Patent Index - EP 1093464 A2

EP 1093464 A2 2001-04-25 - COMPOUNDS, COMPOSITIONS AND METHODS FOR THE ENDOCYTIC PRESENTATION OF IMMUNOSUPPRESSIVE FACTORS

Title (en)

COMPOUNDS, COMPOSITIONS AND METHODS FOR THE ENDOCYTIC PRESENTATION OF IMMUNOSUPPRESSIVE FACTORS

Title (de)

VERBINDUNGEN, ZUSAMMENSETZUNGEN UND VERFAHREN ZUR ENDOZYTISCHEN PRÄSENTATION IMMUNSUPPRESSIVER FAKTOREN

Title (fr)

COMPOSES, COMPOSITIONS ET PROCEDES DESTINES A LA PRESENTATION ENDOCYTIQUE DE FACTEURS IMMUNOSUPPRESSEURS

Publication

EP 1093464 A2 (EN)

Application

EP 99935427 A

Priority

  • US 9915225 W
  • US 11112398 A

Abstract (en)

[origin: WO0001732A2] A fusion protein for the alleviation of symptoms associated with an autoimmune disorder comprising an immunoglobulin or portion thereof linked to one or more autoantigenic polypeptides or fragments thereof, wherein said immunoglobulin or portion thereof is capable of binding to an Fc receptor and being endocytosed by an antigen-presenting cell, and said one or more autoantigenic polypeptides or fragments thereof provides more than one T cell receptor peptide agonist for presentation on the surface of said antigen-presenting cell upon endocytic processing. Said autoantigenic polypeptides may comprise at least a portion of myelin basic protein or at least a portion of proteolipid protein. Method to alleviate symptoms associated with an autoimmune disorder in a patient in need thereof comprising the steps of providing a composition comprising said fusion protein and administering a therapeutically effective amount of said composition to said patient. Autoimmune disorders may include multiple sclerosis, lupus, rheumatoid arthritis, scleroderma, insulin-dependent diabetes and ulcerative colitis. Method for presenting multiple T cell receptor agonists on the surface of a professional or nonprofessional antigen-presenting cell comprising the steps of providing said fusion protein, contacting said fusion protein with at least one Fc receptor present on the surface of a professional or nonprofessional antigen-presenting cell, whereby the fusion protein is internalized by the antigen-presenting cell, and endocytically processing the internalized fusion protein to provide more than one T cell receptor peptide agonist, wherein the provided T cell receptor agonists are presented on the surface of the antigen-presenting cell.

IPC 1-7 (main, further and additional classification)

C07K 19/00; A61K 39/00

IPC 8 full level (invention and additional information)

C07K 19/00 (2006.01); A61K 39/00 (2006.01); C07K 14/47 (2006.01); C07K 16/00 (2006.01); A61K 38/00 (2006.01)

CPC (invention and additional information)

C07K 16/00 (2013.01); C07K 14/4713 (2013.01); A61K 38/00 (2013.01); A61K 2039/505 (2013.01); C07K 2317/73 (2013.01); C07K 2317/77 (2013.01); C07K 2319/00 (2013.01)

Designated contracting state (EPC)

AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

EPO simple patent family

WO 0001732 A2 20000113; WO 0001732 A3 20000427; AU 5090899 A 20000124; CA 2331771 A1 20000113; EP 1093464 A2 20010425

INPADOC legal status


2009-05-13 [18D] DEEMED TO BE WITHDRAWN

- Effective date: 20081111

2008-07-23 [DAX] REQUEST FOR EXTENSION OF THE EUROPEAN PATENT (TO ANY COUNTRY) DELETED

2008-07-23 [RIC1] CLASSIFICATION (CORRECTION)

- IPC: C07K 19/00 20060101AFI20080618BHEP

2008-07-23 [RIC1] CLASSIFICATION (CORRECTION)

- IPC: A61K 39/00 20060101ALI20080618BHEP

2007-12-19 [17Q] FIRST EXAMINATION REPORT

- Effective date: 20071114

2007-01-10 [RAP1] TRANSFER OF RIGHTS OF AN EP PUBLISHED APPLICATION

- Owner name: UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION

2001-04-25 [17P] REQUEST FOR EXAMINATION FILED

- Effective date: 20010206

2001-04-25 [AK] DESIGNATED CONTRACTING STATES:

- Kind Code of Ref Document: A2

- Designated State(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

2001-04-25 [AX] REQUEST FOR EXTENSION OF THE EUROPEAN PATENT TO

- Free text: AL;LT;LV;MK;RO;SI